α4β7 integrin binding proteins and methods of use

[0001] This application is a continuation of International Application No. PCT/US2024/042242, filed Aug. 14, 2024, which claims the benefit of and priority to U.S. Provisional Application No. 63/519,483, filed on Aug. 14, 2023, the entire content of each of which is incorporated herein by reference.

[0002] This application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy, created on Mar. 31, 2025, is titled 220703-010302_US_SL.xml and is 1,927,278 bytes in size.

[0003] Integrins are cell-adhesion transmembrane receptors that function as extracellular matrix (ECM)-cytoskeletal linkers and transducers of biochemical and mechanical signals between cells and their environment. Due to their exposure on the cell surface and sensitivity to molecular inhibition, integrins such as α4β7 integrin have been investigated as pharmacological targets for treating various diseases including cancer and inflammatory diseases (e.g., inflammatory bowel disease). However, current integrin therapies have been associated with serious side effects given the role of integrins in important biological processes and/or require multiple and frequent doses to maintain therapeutic efficacy. As such, improved α4β7 integrin therapies are needed.

[0004] Described herein, in certain embodiments, are α4β7 binding proteins comprising: a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 3, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 109, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 215; and a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 321, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 427, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 533; b) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 4, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 110, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 216; and a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 322, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 428, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 534; c) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 5, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 111, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 217; and a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 323, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 429, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 535; d) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 6, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 112, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 218; and a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 324, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 430, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 536; e) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 81, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 187, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 293; and a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 399, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 505, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 611; f) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 82, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 188, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 294; and a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 400, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 506, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 612; or g) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 83, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 189, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 295; and a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 401, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 507, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 613.

[0005] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1911-1914 and 1925-1927; and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 2017-2020 and 2031-2033.

[0006] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1911 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2017.

[0007] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1912 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2018.

[0008] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1913 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2019.

[0009] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1914 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2020.

[0010] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1925 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2031.

[0011] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1926 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2032.

[0012] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1927 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2033.

[0013] Described herein, in certain embodiments, are α4β7 binding proteins comprising: a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 7-26, 32-58, 60-80, and 84-106; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 113-132, 138-164, 166-186, and 190-212; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 219-238, 244-270, 272-292, and 296-318; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 325-344, 350-376, 378-398, and 402-424; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 431-450, 456-482, 484-504, and 508-530; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 537-556, 562-588, 590-610, and 614-636.

[0014] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 7; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 113; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 219; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 325; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 431; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 537.

[0015] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 8; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 114; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 220; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 326; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 432; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 538.

[0016] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 9; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 115; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 221; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 327; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 433; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 539.

[0017] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 10; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 116; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 222; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 328; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 434; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 540.

[0018] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 11; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 117; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 223; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 329; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 435; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 541.

[0019] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 12; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 118; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 224; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 330; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 436; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 542.

[0020] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 13; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 119; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 225; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 331; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 437; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 543.

[0021] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 14; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 120; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 226; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 332; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 438; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 544.

[0022] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 15; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 121; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 227; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 333; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 439; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 545.

[0023] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 16; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 122; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 228; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 334; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 440; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 546.

[0024] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 17; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 123; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 229; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 335; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 441; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 547.

[0025] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 18; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 124; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 230; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 336; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 442; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 548.

[0026] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 19; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 125; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 231; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 337; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 443; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 549.

[0027] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 20; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 126; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 232; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 338; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 444; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 550.

[0028] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 21; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 127; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 233; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 339; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 445; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 551.

[0029] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 22; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 128; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 234; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 340; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 446; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 552.

[0030] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 23; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 129; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 235; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 341; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 447; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 553.

[0031] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 24; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 130; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 236; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 342; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 448; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 554.

[0032] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 25; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 131; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 237; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 343; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 449; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 555.

[0033] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 26; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 132; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 238; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 344; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 450; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 556.

[0034] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 32; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 138; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 244; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 350; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 456; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 562.

[0035] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 33; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 139; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 245; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 351; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 457; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 563.

[0036] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 34; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 140; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 246; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 352; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 458; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 564.

[0037] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 35; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 141; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 247; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 353; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 459; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 565.

[0038] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 36; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 142; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 248; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 354; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 460; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 566.

[0039] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 37; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 143; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 249; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 355; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 461; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 567.

[0040] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 38; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 144; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 250; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 356; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 462; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 568.

[0041] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 39; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 145; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 251; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 357; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 463; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 569.

[0042] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 40; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 146; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 252; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 358; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 464; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 570.

[0043] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 41; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 147; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 253; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 359; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 465; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 571.

[0044] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 42; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 148; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 254; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 360; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 466; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 572.

[0045] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 43; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 149; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 255; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 361; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 467; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 573.

[0046] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 44; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 150; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 256; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 362; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 468; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 574.

[0047] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 45; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 151; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 257; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 363; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 469; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 575.

[0048] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 46; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 152; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 258; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 364; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 470; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 576.

[0049] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 47; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 153; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 259; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 365; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 471; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 577.

[0050] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 48; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 154; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 260; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 366; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 472; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 578.

[0051] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 49; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 155; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 261; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 367; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 473; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 579.

[0052] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 50; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 156; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 262; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 368; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 474; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 580.

[0053] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 51; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 157; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 263; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 369; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 475; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 581.

[0054] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 52; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 158; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 264; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 370; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 476; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 582.

[0055] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 53; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 159; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 265; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 371; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 477; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 583.

[0056] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 54; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 160; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 266; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 372; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 478; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 584.

[0057] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 55; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 161; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 267; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 373; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 479; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 585.

[0058] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 56; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 162; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 268; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 374; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 480; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 586.

[0059] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 57; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 163; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 269; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 375; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 481; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 587.

[0060] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 58; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 164; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 270; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 376; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 482; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 588.

[0061] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 60; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 166; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 272; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 378; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 484; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 590.

[0062] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 61; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 167; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 273; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 379; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 485; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 591.

[0063] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 62; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 168; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 274; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 380; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 486; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 592.

[0064] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 63; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 169; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 275; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 381; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 487; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 593.

[0065] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 64; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 170; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 276; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 382; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 488; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 594.

[0066] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 65; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 171; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 277; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 383; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 489; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 595.

[0067] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 66; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 172; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 278; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 384; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 490; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 596.

[0068] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 67; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 173; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 279; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 385; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 491; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 597. In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 68; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 174; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 280; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 386; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 492; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 598.

[0069] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 69; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 175; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 281; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 387; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 493; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 599.

[0070] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 70; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 176; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 282; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 388; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 494; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 600.

[0071] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 71; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 177; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 283; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 389; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 495; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 601.

[0072] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 72; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 178; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 284; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 390; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 496; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 602.

[0073] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 73; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 179; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 285; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 391; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 497; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 603.

[0074] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 74; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 180; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 286; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 392; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 498; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 604.

[0075] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 75; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 181; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 287; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 393; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 499; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 605.

[0076] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 76; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 182; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 288; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 394; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 500; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 606.

[0077] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 77; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 183; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 289; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 395; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 501; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 607.

[0078] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 78; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 184; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 290; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 396; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 502; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 608.

[0079] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 79; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 185; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 291; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 397; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 503; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 609.

[0080] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 80; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 186; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 292; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 398; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 504; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 610.

[0081] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 84; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 190; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 2%; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 402; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 508; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 614.

[0082] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 85; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 191; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 297; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 403; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 509; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 615.

[0083] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 86; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 192; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 298; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 404; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 510; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 616.

[0084] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 87; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 193; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 299; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 405; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 511; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 617.

[0085] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 88; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 194; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 300; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 406; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 512; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 618.

[0086] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 89; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 195; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 301; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 407; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 513; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 619.

[0087] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 90; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 196; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 302; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 408; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 514; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 620.

[0088] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 91; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 197; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 303; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 409; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 515; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 621.

[0089] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 92; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 198; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 304; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 410; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 516; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 622.

[0090] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 93; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 199; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 305; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 411; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 517; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 623.

[0091] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 94; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 200; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 306; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 412; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 518; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 624.

[0092] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 95; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 201; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 307; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 413; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 519; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 625.

[0093] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 96; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 202; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 308; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 414; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 520; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 626.

[0094] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 97; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 203; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 309; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 415; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 521; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 627.

[0095] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 98; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 204; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 310; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 416; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 522; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 628.

[0096] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 99; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 205; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 311; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 417; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 523; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 629.

[0097] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 100; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 206; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 312; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 418; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 524; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 630.

[0098] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 101; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 207; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 313; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 419; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 525; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 631.

[0099] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 102; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 208; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 314; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 420; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 526; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 632.

[0100] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 103; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 209; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 315; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 421; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 527; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 633.

[0101] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 104; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 210; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 316; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 422; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 528; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 634.

[0102] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 105; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 211; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 317; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 423; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 529; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 635.

[0103] In some embodiments, the VH comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 106; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 212; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 318; and the VL comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 424; (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 530; and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 636.

[0104] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1915-1934, 1940-1966, 1968-1988, and 1992-2014; and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 2021-2040, 2046-2072, 2074-2094, and 2098-2120.

[0105] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 127 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 134.

[0106] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1915 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2021.

[0107] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1916 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2022.

[0108] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1917 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2023.

[0109] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1918 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2024.

[0110] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1919 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2025.

[0111] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1920 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2026.

[0112] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1921 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2027.

[0113] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1922 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2028.

[0114] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1923 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2029.

[0115] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1924 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2030.

[0116] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1925 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2031.

[0117] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1926 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2032.

[0118] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1927 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2033.

[0119] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1928 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2034.

[0120] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1929 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2035.

[0121] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1930 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2036.

[0122] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1931 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2037.

[0123] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1932 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2038.

[0124] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1933 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2039.

[0125] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1934 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2040.

[0126] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1940 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2046.

[0127] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1941 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2047.

[0128] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1942 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2048.

[0129] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1943 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2049.

[0130] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1944 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2050.

[0131] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1945 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2051.

[0132] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1946 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2052.

[0133] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1947 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2053.

[0134] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1948 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2054.

[0135] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1949 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2055.

[0136] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1950 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2056.

[0137] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1951 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2057.

[0138] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1952 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2058.

[0139] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1953 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2059.

[0140] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1954 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2060.

[0141] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1955 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2061.

[0142] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1956 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2062.

[0143] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1957 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2063.

[0144] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1958 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2064.

[0145] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1959 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2065.

[0146] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1960 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2066.

[0147] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1961 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2067.

[0148] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1962 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2068.

[0149] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1963 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2069.

[0150] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1964 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2070.

[0151] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1965 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2071.

[0152] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1966 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2072.

[0153] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1968 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2074.

[0154] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1969 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2075.

[0155] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1970 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2076.

[0156] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1971 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2077.

[0157] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1972 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2078.

[0158] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1973 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2079.

[0159] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1974 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2080.

[0160] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1975 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2081.

[0161] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1976 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2082.

[0162] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1977 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2083.

[0163] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1978 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2084.

[0164] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1979 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2085.

[0165] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1980 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2086.

[0166] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1981 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2087.

[0167] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1982 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2088.

[0168] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1983 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2089.

[0169] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1984 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2090.

[0170] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1985 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2091.

[0171] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1986 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2092.

[0172] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1987 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2093.

[0173] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1992 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2098.

[0174] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1993 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2099.

[0175] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1994 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2100.

[0176] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1995 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2101.

[0177] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1996 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2102.

[0178] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1997 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2103.

[0179] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1998 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2104.

[0180] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1999 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2105.

[0181] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2000 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2106.

[0182] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2001 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2107.

[0183] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2002 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2108.

[0184] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2003 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2109.

[0185] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2004 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2110.

[0186] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2005 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2111.

[0187] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2006 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2112.

[0188] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2007 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2113.

[0189] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2008 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2114.

[0190] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2009 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2115.

[0191] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2010 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2116.

[0192] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2011 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2117.

[0193] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2012 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2118.

[0194] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2013 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2119.

[0195] In some embodiments, the VH comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2014 and the VL comprises a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2120.

[0196] Described herein, in certain embodiments, are α4β7 binding proteins comprising: a) a heavy chain variable region (VH) comprising the amino acid sequence according to any one of SEQ ID NOs: 1909, 1910, 1935-1939, 1967; and b) a light chain variable region (VL) comprising the amino acid sequence according to any one of SEQ ID NOs: 2015, 2016, 2041-2045, 2073.

[0197] In some embodiments, the VH comprises the amino acid sequence according to SEQ ID NO: 1909; and the VL comprises the amino acid sequence according to SEQ ID NO: 2015.

[0198] In some embodiments, the VH comprises the amino acid sequence according to SEQ ID NO: 1910; and the VL comprises the amino acid sequence according to SEQ ID NO: 2016.

[0199] In some embodiments, the VH comprises the amino acid sequence according to SEQ ID NO: 1935; and the VL comprises the amino acid sequence according to SEQ ID NO: 2041.

[0200] In some embodiments, the VH comprises the amino acid sequence according to SEQ ID NO: 1936; and the VL comprises the amino acid sequence according to SEQ ID NO: 2042.

[0201] In some embodiments, the VH comprises the amino acid sequence according to SEQ ID NO: 1937; and the VL comprises the amino acid sequence according to SEQ ID NO: 2043.

[0202] In some embodiments, the VH comprises the amino acid sequence according to SEQ ID NO: 1938; and the VL comprises the amino acid sequence according to SEQ ID NO: 2044.

[0203] In some embodiments, the VH comprises the amino acid sequence according to SEQ ID NO: 1939; and the VL comprises the amino acid sequence according to SEQ ID NO: 2045.

[0204] In some embodiments, the VH comprises the amino acid sequence according to SEQ ID NO: 1967; and the VL comprises the amino acid sequence according to SEQ ID NO: 2073.

[0205] Described herein, in certain embodiments, are α4β7 binding proteins comprising: a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 1-106, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 107-212, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 213-318; b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 319-424, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 425-530, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 531-636; and c) a modified Fc that comprises amino acid modifications M252Y, S254T, and T256E (YTE) and/or L234A/G237A (LAGA).

[0206] Described herein, in certain embodiments, are α4β7 binding proteins comprising: a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 1-106, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 107-212, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 213-318; b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 319-424, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 425-530, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 531-636; and c) a modified Fc that extends half-life of the α4β7 binding protein as compared to an α4β7 binding protein that does not comprise the modified Fc.

[0207] Described herein, in certain embodiments, are α4β7 binding proteins, wherein the α4β7 binding protein specifically binds to an epitope of α4β7 and comprises a Fc domain comprising amino acid modifications M252Y, S254T, and T256E (YTE) and/or L234A/G237A (LAGA).

[0208] In some embodiments, the Fc is an IgG1, IgG2 or IgG4 immunoglobulin Fc domain.

[0209] In some embodiments, the Fc is an IgG1 immunoglobulin domain.

[0210] In some embodiments, the Fc is an IgG2 immunoglobulin domain.

[0211] In some embodiments, the Fc is an IgG4 immunoglobulin domain.

[0212] In some embodiments, the α4β7 binding protein is an antibody.

[0213] Aspects of the disclosure relate to compositions comprising the α4β7 binding proteins described herein and a pharmaceutically acceptable carrier. Also provided herein are injectable liquid compositions comprising the α4β7 binding proteins described herein and a pharmaceutically acceptable carrier.

[0214] Aspects of the disclosure relate to nucleic acid encoding the α4β7 binding proteins described herein. In some embodiments, provided herein are recombinant host cells comprised the nucleic acid encoding the α4β7 binding proteins described herein.

[0215] Aspects of the disclosure relate to methods of treating an inflammatory bowel disease in a patient in need thereof, the method comprising subcutaneously or intravenously administering to the patient an effective amount of an α4β7 binding protein described herein. In some embodiments, the inflammatory bowel disease is Crohn's disease or ulcerative colitis. In some embodiments, the inflammatory bowel disease is ulcerative colitis. In some embodiments, the inflammatory bowel disease is Crohn's disease. In some embodiments, administration of the α4β7 binding protein is subcutaneous. In some embodiments, administration of the α4β7 binding protein is intravenous.

[0216] Aspects of the disclosure relate to methods of treating an inflammatory disease in a patient in need thereof, the method comprising subcutaneously or intravenously administering to the patient an effective amount of an α4β7 binding protein described herein. In some embodiments, the inflammatory disease is hidradenitis suppurativa. In some embodiments, administration of the α4β7 binding protein is subcutaneous. In some embodiments, administration of the α4β7 binding protein is intravenous.

[0221] To facilitate an understanding of the present disclosure, a number of terms and phrases are defined below.

[0222] As used herein, unless otherwise indicated, the term “antibody” is understood to mean an intact antibody (e.g., an intact monoclonal antibody), or a fragment thereof, such as a Fc fragment of an antibody (e.g., an Fc fragment of a monoclonal antibody), or an antigen-binding fragment of an antibody (e.g., an antigen-binding fragment of a monoclonal antibody), including an intact antibody, antigen-binding fragment, or Fc fragment that has been modified, engineered, or chemically conjugated. In general, antibodies are multimeric proteins that contain four polypeptide chains. Two of the polypeptide chains are called immunoglobulin heavy chains (H chains), and two of the polypeptide chains are called immunoglobulin light chains (L chains). The immunoglobulin heavy and light chains are connected by an interchain disulfide bond. The immunoglobulin heavy chains are connected by interchain disulfide bonds. A light chain consists of one variable region (VL) and one constant region (CL). The heavy chain consists of one variable region (VH) and at least three constant regions (CH1, CH2 and CH3). The variable regions determine the binding specificity of the antibody. Each variable region contains three hypervariable regions known as complementarity determining regions (CDRs) flanked by four relatively conserved regions known as framework regions (FRs). The extent of the FRs and CDRs has been defined (Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917). The three CDRs, referred to as CDR1, CDR2, and CDR3, contribute to the antibody binding specificity. Naturally occurring antibodies have been used as starting material for engineered antibodies, such as chimeric antibodies and humanized antibodies. Examples of antibody-based antigen-binding fragments include Fab, Fab′, (Fab′)2, Fv, single chain antibodies (e.g., scFv), minibodies, and diabodies. Examples of antibodies that have been modified or engineered include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies). An example of a chemically conjugated antibody is an antibody conjugated to a toxin moiety.

[0223] The terms “variable domain” and “variable region” are used interchangeably and refer to the portions of the antibody or immunoglobulin domains that exhibit variability in their sequence and that are involved in determining the specificity and binding affinity of a particular antibody. Variability is not evenly distributed throughout the variable domains of antibodies; it is concentrated in sub-domains of each of the heavy and light chain variable regions. These sub-domains are called “hypervariable regions” or “complementarity determining regions” (CDRs). The more conserved (i.e., non-hypervariable) portions of the variable domains are called the “framework” regions (FRM or FR) and provide a scaffold for the six CDRs in three-dimensional space to form an antigen-binding surface.

[0224] An “Fc polypeptide” of a dimeric Fc as used herein refers to one of the two polypeptides forming the dimeric Fc domain, i.e. a polypeptide comprising C-terminal constant regions of an immunoglobulin heavy chain, capable of stable self-association. For example, an Fc polypeptide of a dimeric IgG Fc comprises an IgG CH2 and an IgG CH3 constant domain sequence. An Fc can be of the class IgA, IgD, IgE, IgG, and IgM. These classes are also designated α, δ, ε, γ, and μ, respectively. Several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0225] The terms “Fc receptor” and “FcR” are used to describe a receptor that binds to the Fc region of an antibody. For example, an FcR can be a native sequence human FcR. Generally, an FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (an “activating receptor”) and FcγRIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Immunoglobulins of other isotypes can also be bound by certain FcRs (see, e.g., Janeway et al., Immuno Biology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999)). Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (reviewed in Dafron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term “FcR” herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976); and Kim et al., J. Immunol. 24:249 (1994)).

[0226] The terms “recipient”, “individual”, “subject”, “host”, and “patient”, are used interchangeably herein and in some embodiments, refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans. “Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and laboratory, zoo, sports, or pet animals, such as dogs, horses, cats, cows, sheep, goats, pigs, mice, rats, rabbits, guinea pigs, monkeys etc. In some embodiments, the mammal is human. None of these terms require the supervision of medical personnel.

[0227] As used herein, the term “effective amount” refers to the amount of a compound (e.g., a compound of the present disclosure) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.

[0228] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.

[0229] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA (1975).

[0230] The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.

[0231] As used herein, all numerical values or numerical ranges include whole integers within or encompassing such ranges and fractions of the values or the integers within or encompassing ranges unless the context clearly indicates otherwise. Thus, for example, reference to a range of 90-100%, includes 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so forth. In another example, reference to a range of 1-5,000-fold includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, fold, etc., as well as 1.1, 1.2, 1.3, 1.4, 1.5, fold, etc., 2.1, 2.2, 2.3, 2.4, 2.5, fold, etc., and so forth.

[0232] “About” a number, as used herein, refers to range including the number and ranging from 10% below that number to 10% above that number. “About” a range refers to 10% below the lower limit of the range, spanning to 10% above the upper limit of the range.

[0233] “Percent (%) identity” refers to the extent to which two sequences (nucleotide or amino acid) have the same residue at the same positions in an alignment. For example, “an amino acid sequence is X % identical to SEQ ID NO: Y” refers to % identity of the amino acid sequence to SEQ ID NO: Y and is elaborated as X % of residues in the amino acid sequence are identical to the residues of sequence disclosed in SEQ ID NO: Y. Generally, computer programs are employed for such calculations. Exemplary programs that compare and align pairs of sequences include ALIGN (Myers and Miller, 1988), FASTA (Pearson and Lipman, 1988; Pearson, 1990) and gapped BLAST (Altschul et al., 1997), BLASTP, BLASTN, or GCG (Devereux et al., 1984).

[0234] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present disclosure that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present disclosure that consist essentially of, or consist of, the recited processing steps.

[0235] As a general matter, compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.

α4β7 Integrin Binding Proteins

[0236] Provided herein are α4β7 integrin binding proteins. In some embodiments, the α4β7 integrin binding protein is an antibody. In certain embodiments α4β7 integrin binding proteins comprise a modified Fc that extends half-life of the α4β7 binding protein as compared to an α4β7 binding protein that does not comprise the modified Fc.

[0237] Further described herein, in certain embodiments, are α4β7 integrin binding proteins, wherein the α4β7 binding protein specifically binds to an epitope of α4β7 and comprises a Fc domain comprising amino acid modifications M252Y, S254T, and T256E (YTE) and/or L234A/G237A (LAGA).

[0238] Amino acid sequences of exemplary CDRs of α4β7 integrin binding proteins are provided in Table 1.

[0239]

TABLE 1
Sequences of CDRs
Kabat Numbering
	SEQ ID		SEQ ID		SEQ ID		SEQ ID		SEQ ID		SEQ ID
Antibody	NO	CDRH1	NO	CDRH2	NO	CDRH3	NO	CDRL1	NO	CDRL2	NO	CDRL3
Antibody 1	1	SYWMH	107	EIDPSES	213	GGYDG	319	RSSQSL	425	GISNRF	531	LQGTH
				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody 2	2	SYWMH	108	EIDPSES	214	GGYDG	320	RSSQSL	426	GISNRF	532	LQGTH
				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody 3	3	IYWMH	109	EIDPSES	215	GGYDG	321	RSSQSL	427	GISNRF	533	LQGTH
				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody 4	4	VYWMH	110	EIDPSES	216	GGYDG	322	RSSQSL	428	GISNRF	534	LQGTH
				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody 5	5	SMWMH	111	EIDPSES	217	GGYDG	323	RSSQSL	429	GISNRF	535	LQGTH
				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody 6	6	SQWMH	112	EIDPSES	218	GGYDG	324	RSSQSL	430	GISNRF	536	LQGTH
				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody 7	7	SYWMH	113	EIIPSES	219	GGYDG	325	RSSQSL	431	GISNRF	537	LQGTH
				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody 8	8	SYWMH	114	EIIPLES	220	GGYDG	326	RSSQSL	432	GISNRF	538	LQGTH
				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody 9	9	SYWMH	115	EIIPRES	221	GGYDG	327	RSSQSL	433	GISNRF	539	LQGTH
				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	10	SYWMH	116	EIIPVES	222	GGYDG	328	RSSQSL	434	GISNRF	540	LQGTH
10				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	11	SYWMH	117	EIRPSES	223	GGYDG	329	RSSQSL	435	GISNRF	541	LQGTH
11				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	12	SYWMH	118	EIRPLES	224	GGYDG	330	RSSQSL	436	GISNRF	542	LQGTH
12				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	13	SYWMH	119	EIRPRES	225	GGYDG	331	RSSQSL	437	GISNRF	543	LQGTH
13				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	14	SYWMH	120	EIRPVES	226	GGYDG	332	RSSQSL	438	GISNRF	544	LQGTH
14				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	15	SYWMH	121	EIDPLES	227	GGYDG	333	RSSQSL	439	GISNRF	545	LQGTH
15				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	16	SYWMH	122	EIDPME	228	GGYDG	334	RSSQSL	440	GISNRF	546	LQGTH
16				SNTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	17	SYWMH	123	EIDPRES	229	GGYDG	335	RSSQSL	441	GISNRF	547	LQGTH
17				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	18	SYWMH	124	EIDPVE	230	GGYDG	336	RSSQSL	442	GISNRF	548	LQGTH
18				SNTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	19	SYWMH	125	EIDPSES	231	GGYDG	337	RSSQSL	443	GISNRF	549	LQGTH
19				NTNYN		WDYFID		AKSYG		S		QPYT
				QKFKG		Y		NTYLS
Antibody	20	SYWMH	126	EIDPSES	232	GGYDG	338	RSSQSL	444	GISNRF	550	LQGTH
20				NTNYN		WDYFIY		AKSYG		S		QPYT
				QKFKG		Y		NTYLS
Antibody	21	SYWMH	127	EIDPSES	233	GGYDG	339	RSSQSL	445	GISNRF	551	LQGTH
21				NTNYN		WDYLID		AKSYG		S		QPYT
				QKFKG		Y		NTYLS
Antibody	22	SYWMH	128	EIDPSES	234	GGYDG	340	RSSQSL	446	GISNRF	552	LQGTH
22				NTNYN		WDYVI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	23	SYWMH	129	EIDPSES	235	GGYDG	341	RSSQSL	447	GISNRF	553	LQGTH
23				NTNYN		WDYVI		AKSYG		S		QPYT
				QKFKG		YY		NTYLS
Antibody	24	SYWMH	130	EIDPSES	236	GGYDG	342	RSSQSL	448	GISNRF	554	LQGTH
24				NTNYN		WDYWI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	25	SYWMH	131	EIDPSES	237	GGYDG	343	RSSQSL	449	GISNRF	555	LQGTH
25				NTNYN		WDYYI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	26	SYWMH	132	EIDPSES	238	GGYDG	344	RSSQSL	450	GISNRF	556	LQGTH
26				NTNYN		WDYYI		AKSYG		S		QPYT
				QKFKG		YY		NTYLS
Antibody	27	SYWMH	133	EIDPSES	239	GGYDG	345	RSSQSL	451	GISNRF	557	LQGTH
27				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	28	SYWMH	134	EIDPSES	240	GGYDG	346	RSSQSL	452	GISNRF	558	LQGTH
28				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	29	SYWMH	135	EIDPSES	241	GGYDG	347	RSSQSL	453	GISNRF	559	LOGTH
29				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	30	SYWMH	136	EIDPSES	242	GGYDG	348	RSSQSL	454	GISNRF	560	LQGTH
30				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	31	SYWMH	137	EIDPSES	243	GGYDG	349	RSSQSL	455	GISNRF	561	LQGTH
31				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	32	SYWMH	138	EIDPSES	244	GGYWG	350	RSSQSL	456	GISNRF	562	LQGTH
32				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	33	SYWMH	139	EIDPSES	245	GGYYG	351	RSSQSL	457	GISNRF	563	LQGTH
33				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	34	SYWMH	140	EIDPSES	246	GGYDG	352	RSSQSL	458	GISNRF	564	LQGTH
34				NTNYN		WDYAIF		AKSYG		S		QPYT
				QKFKG		Y		NTYLS
Antibody	35	SYWMH	141	EIDPSES	247	GGYDG	353	RSSQSL	459	GISNRF	565	LQGTH
35				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		MY		NTYLS
Antibody	36	SYWMH	142	EIDPSES	248	GGYDG	354	RSSQSL	460	GISNRF	566	LQGTH
36				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		WY		NTYLS
Antibody	37	SYWMH	143	EIDPSES	249	GGYDG	355	RSSQSL	461	GISNRF	567	LQGTH
37				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		YY		NTYLS
Antibody	38	SYWMH	144	EIDPSES	250	GFYDG	356	RSSQSL	462	GISNRF	568	LQGTH
38				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	39	SYWMH	145	EIDPSES	251	GFYDG	357	RSSQSL	463	GISNRF	569	LQGTH
39				NTNYN		WDYLID		AKSYG		S		QPYT
				QKFKG		Y		NTYLS
Antibody	40	SYWMH	146	EIDPSES	252	GFYDG	358	RSSQSL	464	GISNRF	570	LQGTH
40				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		YY		NTYLS
Antibody	41	SYWMH	147	EIDPSES	253	GMYDG	359	RSSQSL	465	GISNRF	571	LQGTH
41				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	42	SYWMH	148	EIDPSES	254	GRYDG	360	RSSQSL	466	GISNRF	572	LQGTH
42				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	43	SYWMH	149	EIDPSES	255	GVYDG	361	RSSQSL	467	GISNRF	573	LQGTH
43				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	44	SYWMH	150	EIDPSES	256	GGYDI	362	RSSQSL	468	GISNRF	574	LQGTH
44				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	45	SYWMH	151	EIDPSES	257	GGYDL	363	RSSQSL	469	GISNRF	575	LQGTH
45				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	46	SYWMH	152	EIDPSES	258	GGYDV	364	RSSQSL	470	GISNRF	576	LQGTH
46				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	47	SYWMH	153	EIDPSES	259	FGYDG	365	RSSQSL	471	GISNRF	577	LQGTH
47				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	48	SYWMH	154	EIDPSES	260	YGYDG	366	RSSQSL	472	GISNRF	578	LQGTH
48				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	49	SYWMH	155	EIDPSES	261	GGYDG	367	RSSQSL	473	GISNRF	579	LQGTH
49				NTNYN		WDYAI		AASYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	50	SYWMH	156	EIDPSES	262	GGYDG	368	RSSQSL	474	GISNRF	580	LQGTH
50				NTNYN		WDYAI		ADSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	51	SYWMH	157	EIDPSES	263	GGYDG	369	RSSQSL	475	GISNRF	581	LQGTH
51				NTNYN		WDYAI		AISYGN		S		QPYT
				QKFKG		DY		TYLS
Antibody	52	SYWMH	158	EIDPSES	264	GGYDG	370	RSSQSL	476	GISNRF	582	LQGTH
52				NTNYN		WDYAI		AIFYGN		S		QPYT
				QKFKG		DY		TYLS
Antibody	53	SYWMH	159	EIDPSES	265	GGYDG	371	RSSQSL	477	GISNRF	583	LQGTH
53				NTNYN		WDYAI		AIFYGIT		S		QPYT
				QKFKG		DY		YLS
Antibody	54	SYWMH	160	EIDPSES	266	GGYDG	372	RSSQSL	478	GISNRF	584	LQGTH
54				NTNYN		WDYAI		AIFYGL		S		QPYT
				QKFKG		DY		TYLS
Antibody	55	SYWMH	161	EIDPSES	267	GGYDG	373	RSSQSL	479	GISNRF	585	LQGTH
55				NTNYN		WDYAI		AILYGIT		S		QPYT
				QKFKG		DY		YLS
Antibody	56	SYWMH	162	EIDPSES	268	GGYDG	374	RSSQSL	480	GISNRF	586	LQGTH
				NTNYN		WDYAI		AILYGL
56				QKFKG		DY		TYLS		S		QPYT
Antibody	57	SYWMH	163	EIDPSES	269	GGYDG	375	RSSQSL	481	GISNRF	587	LQGTH
57				NTNYN		WDYAI		ALSYGN		S		QPYT
				QKFKG		DY		TYLS
Antibody	58	SYWMH	164	EIDPSES	270	GGYDG	376	RSSQSL	482	GISNRF	588	LQGTH
58				NTNYN		WDYAI		AMSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	59	SYWMH	165	EIDPSES	271	GGYDG	377	RSSQSL	483	GISNRF	589	LQGTH
59				NTNYN		WDYAI		ANSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	60	SYWMH	166	EIDPSES	272	GGYDG	378	RSSQSL	484	GISNRF	590	LQGTH
60				NTNYN		WDYAI		APSYGN		S		QPYT
				QKFKG		DY		TYLS
Antibody	61	SYWMH	167	EIDPSES	273	GGYDG	379	RSSQSL	485	GISNRF	591	LQGTH
61				NTNYN		WDYAI		AQSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	62	SYWMH	168	EIDPSES	274	GGYDG	380	RSSQSL	486	GISNRF	592	LQGTH
62				NTNYN		WDYAI		ARSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	63	SYWMH	169	EIDPSES	275	GGYDG	381	RSSQSL	487	GISNRF	593	LQGTH
63				NTNYN		WDYAI		ARFYGL		S		QPYT
				QKFKG		DY		TYLS
Antibody	64	SYWMH	170	EIDPSES	276	GGYDG	382	RSSQSL	488	GISNRF	594	LQGTH
64				NTNYN		WDYAI		ASSYGN		S		QPYT
				QKFKG		DY		TYLS
Antibody	65	SYWMH	171	EIDPSES	277	GGYDG	383	RSSQSL	489	GISNRF	595	LQGTH
65				NTNYN		WDYAI		ATSYGN		S		QPYT
				QKFKG		DY		TYLS
Antibody	66	SYWMH	172	EIDPSES	278	GGYDG	384	RSSQSL	490	GISNRF	596	LQGTH
66				NTNYN		WDYAI		ATYYGI		S		QPYT
				QKFKG		DY		TYLS
Antibody	67	SYWMH	173	EIDPSES	279	GGYDG	385	RSSQSL	491	GISNRF	597	LQGTH
67				NTNYN		WDYAI		ATYYG		S		QPYT
				QKFKG		DY		LTYLS
Antibody	68	SYWMH	174	EIDPSES	280	GGYDG	386	RSSQSL	492	GISNRF	598	LQGTH
68				NTNYN		WDYAI		AVSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	69	SYWMH	175	EIDPSES	281	GGYDG	387	RSSQSL	493	GISNRF	599	LQGTH
69				NTNYN		WDYAI		AYSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	70	SYWMH	176	EIDPSES	282	GGYDG	388	RSSQSL	494	GISNRF	600	LQGTH
70				NTNYN		WDYAI		AYFYGI		S		QPYT
				QKFKG		DY		TYLS
Antibody	71	SYWMH	177	EIDPSES	283	GGYDG	389	RSSQSL	495	GISNRF	601	LQGTH
71				NTNYN		WDYAI		AYLYGI		S		QPYT
				QKFKG		DY		TYLS
Antibody	72	SYWMH	178	EIDPSES	284	GGYDG	390	RSSQSL	496	GISNRF	602	LQGTH
72				NTNYN		WDYAI		AKSYGI		S		QPYT
				QKFKG		DY		TYLS
Antibody	73	SYWMH	179	EIDPSES	285	GGYDG	391	RSSQSL	497	GISNRF	603	LQGTH
73				NTNYN		WDYAI		AKSYGL		S		QPYT
				QKFKG		DY		TYLS
Antibody	74	SYWMH	180	EIDPSES	286	GGYDG	392	RSSQSL	498	GISNRF	604	LQGTH
74				NTNYN		WDYAI		AKFYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	75	SYWMH	181	EIDPSES	287	GGYDG	393	RSSQSL	499	GISNRF	605	LQGTH
75				NTNYN		WDYAI		AKIYGN		S		QPYT
				QKFKG		DY		TYLS
Antibody	76	SYWMH	182	EIDPSES	288	GGYDG	394	RSSQSL	500	GISNRF	606	LQGTH
76				NTNYN		WDYAI		AKLYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	77	SYWMH	183	EIDPSES	289	GGYDG	395	RSSQSL	501	GISNRF	607	LQGTH
77				NTNYN		WDYAI		AKMYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	78	SYWMH	184	EIDPSES	290	GGYDG	396	RSSQSL	502	GISNRF	608	LQGTH
78				NTNYN		WDYAI		AKQYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	79	SYWMH	185	EIDPSES	291	GGYDG	397	RSSQSL	503	GISNRF	609	LQGTH
79				NTNYN		WDYAI		AKYYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	80	SYWMH	186	EIDPSES	292	GGYDG	398	RSSQSL	504	GISNRF	610	LQGTH
80				NTNYN		WDYAI		AKSHG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	81	SYWMH	187	EIDPSES	293	GGYDG	399	RSSQSL	505	FISNRFS	611	LQGTH
81				NTNYN		WDYAI		AKSYG				QPYT
				QKFKG		DY		NTYLS
Antibody	82	SYWMH	188	EIDPSES	294	GGYDG	400	RSSQSL	506	PISNRFS	612	LQGTH
82				NTNYN		WDYAI		AKSYG				QPYT
				QKFKG		DY		NTYLS
Antibody	83	SYWMH	189	EIDPSES	295	GGYDG	401	RSSQSL	507	YISNRF	613	LQGTH
83				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	84	SYWMH	190	EIDPSES	296	GGYDG	402	RSSQSL	508	GISNRF	614	LQFTHQ
84				NTNYN		WDYAI		AKSYG		S		PYT
				QKFKG		DY		NTYLS
Antibody	85	SYWMH	191	EIDPSES	297	GGYDG	403	RSSQSL	509	GISNRF	615	LQFTIQ
85				NTNYN		WDYAI		AKSYG		S		FYT
				QKFKG		DY		NTYLS
Antibody	86	SYWMH	192	EIDPSES	298	GGYDG	404	RSSQSL	510	GISNRF	616	LQFTIQ
86				NTNYN		WDYAI		AKSYG		S		VYT
				QKFKG		DY		NTYLS
Antibody	87	SYWMH	193	EIDPSES	299	GGYDG	405	RSSQSL	511	GISNRF	617	LQFTIQ
87				NTNYN		WDYAI		AKSYG		S		PYI
				QKFKG		DY		NTYLS
Antibody	88	SYWMH	194	EIDPSES	300	GGYDG	406	RSSQSL	512	GISNRF	618	LQFTHQ
88				NTNYN		WDYAI		AKSYG		S		FYT
				QKFKG		DY		NTYLS
Antibody	89	SYWMH	195	EIDPSES	301	GGYDG	407	RSSQSL	513	GISNRF	619	LQFTHQ
89				NTNYN		WDYAI		AKSYG		S		IYI
				QKFKG		DY		NTYLS
Antibody	90	SYWMH	196	EIDPSES	302	GGYDG	408	RSSQSL	514	GISNRF	620	LQFTHQ
90				NTNYN		WDYAI		AKSYG		S		PYI
				QKFKG		DY		NTYLS
Antibody	91	SYWMH	197	EIDPSES	303	GGYDG	409	RSSQSL	515	GISNRF	621	LQRTHQ
91				NTNYN		WDYAI		AKSYG		S		PYT
				QKFKG		DY		NTYLS
Antibody	92	SYWMH	198	EIDPSES	304	GGYDG	410	RSSQSL	516	GISNRF	622	LQRTIQ
92				NTNYN		WDYAI		AKSYG		S		VYI
				QKFKG		DY		NTYLS
Antibody	93	SYWMH	199	EIDPSES	305	GGYDG	411	RSSQSL	517	GISNRF	623	LQRTIQ
93				NTNYN		WDYAI		AKSYG		S		YYT
				QKFKG		DY		NTYLS
Antibody	94	SYWMH	200	EIDPSES	306	GGYDG	412	RSSQSL	518	GISNRF	624	LQVTH
94				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	95	SYWMH	201	EIDPSES	307	GGYDG	413	RSSQSL	519	GISNRF	625	LQWTH
95				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	96	SYWMH	202	EIDPSES	308	GGYDG	414	RSSQSL	520	GISNRF	626	LQYTH
96				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	97	SYWMH	203	EIDPSES	309	GGYDG	415	RSSQSL	521	GISNRF	627	LQYTIQ
97				NTNYN		WDYAI		AKSYG		S		FYI
				QKFKG		DY		NTYLS
Antibody	98	SYWMH	204	EIDPSES	310	GGYDG	416	RSSQSL	522	GISNRF	628	LQYTH
98				NTNYN		WDYAI		AKSYG		S		QFYI
				QKFKG		DY		NTYLS
Antibody	99	SYWMH	205	EIDPSES	311	GGYDG	417	RSSQSL	523	GISNRF	629	LQGTIQ
99				NTNYN		WDYAI		AKSYG		S		PYT
				QKFKG		DY		NTYLS
Antibody	100	SYWMH	206	EIDPSES	312	GGYDG	418	RSSQSL	524	GISNRF	630	LQGTW
100				NTNYN		WDYAI		AKSYG		S		QPYT
				QKFKG		DY		NTYLS
Antibody	101	SYWMH	207	EIDPSES	313	GGYDG	419	RSSQSL	525	GISNRF	631	LOGTH
101				NTNYN		WDYAI		AKSYG		S		QFYT
				QKFKG		DY		NTYLS
Antibody	102	SYWMH	208	EIDPSES	314	GGYDG	420	RSSQSL	526	GISNRF	632	LQGTH
102				NTNYN		WDYAI		AKSYG		S		QIYT
				QKFKG		DY		NTYLS
Antibody	103	SYWMH	209	EIDPSES	315	GGYDG	421	RSSQSL	527	GISNRF	633	LQGTH
103				NTNYN		WDYAI		AKSYG		S		QVYT
				QKFKG		DY		NTYLS
Antibody	104	SYWMH	210	EIDPSES	316	GGYDG	422	RSSQSL	528	GISNRF	634	LQGTH
104				NTNYN		WDYAI		AKSYG		S		QYYT
				QKFKG		DY		NTYLS
Antibody	105	SYWMH	211	EIDPSES	317	GGYDG	423	RSSQSL	529	GISNRF	635	LQGTH
105				NTNYN		WDYAI		AKSYG		S		QPYI
				QKFKG		DY		NTYLS
Antibody	106	SYWMH	212	EIDPSES	318	GGYDG	424	RSSQSL	530	GISNRF	636	LQGTH
106				NTNYN		WDYAI		AKSYG		S		QPYR
				QKFKG		DY		NTYLS
Chothia Numbering
Antibody 1	637	GGTFTS	743	DPSESN	849	GGYDG	955	RSSQSL	1061	GISNRF	1167	LOGTH
		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody 2	638	GYTFTS	744	DPSESN	850	GGYDG	956	RSSQSL	1062	GISNRF	1168	LOGTH
		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody 3	639	GYTFTI	745	DPSESN	851	GGYDG	957	RSSQSL	1063	GISNRF	1169	LQGTH
						WDYAI		AKSYG
		YWMH				DY		NTYLS		S		QPYT
Antibody 4	640	GYTFTV	746	DPSESN	852	GGYDG	958	RSSQSL	1064	GISNRF	1170	LQGTH
		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody 5	641	GYTFTS	747	DPSESN	853	GGYDG	959	RSSQSL	1065	GISNRF	1171	LQGTH
		MWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody 6	642	GYTFTS	748	DPSESN	854	GGYDG	960	RSSQSL	1066	GISNRF	1172	LQGTH
		QWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody 7	643	GYTFTS	749	IPSESN	855	GGYDG	961	RSSQSL	1067	GISNRF	1173	LQGTH
		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody 8	644	GYTFTS	750	IPLESN	856	GGYDG	962	RSSQSL	1068	GISNRF	1174	LQGTH
		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody 9	645	GYTFTS	751	IPRESN	857	GGYDG	963	RSSQSL	1069	GISNRF	1175	LQGTH
		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	646	GYTFTS	752	IPVESN	858	GGYDG	964	RSSQSL	1070	GISNRF	1176	LQGTH
10		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	647	GYTFTS	753	RPSESN	859	GGYDG	965	RSSQSL	1071	GISNRF	1177	LQGTH
11		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	648	GYTFTS	754	RPLESN	860	GGYDG	966	RSSQSL	1072	GISNRF	1178	LOGTH
12		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	649	GYTFTS	755	RPRESN	861	GGYDG	967	RSSQSL	1073	GISNRF	1179	LQGTH
13		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	650	GYTFTS	756	RPVESN	862	GGYDG	968	RSSQSL	1074	GISNRF	1180	LQGTH
14		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	651	GYTFTS	757	DPLESN	863	GGYDG	969	RSSQSL	1075	GISNRF	1181	LQGTH
15		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	652	GYTFTS	758	DPMESN	864	GGYDG	970	RSSQSL	1076	GISNRF	1182	LQGTH
16		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	653	GYTFTS	759	DPRESN	865	GGYDG	971	RSSQSL	1077	GISNRF	1183	LQGTH
17		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	654	GYTFTS	760	DPVESN	866	GGYDG	972	RSSQSL	1078	GISNRF	1184	LQGTH
18		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	655	GYTFTS	761	DPSESN	867	GGYDG	973	RSSQSL	1079	GISNRF	1185	LQGTH
19		YWMH				WDYFID		AKSYG		S		QPYT
						Y		NTYLS
Antibody	656	GYTFTS	762	DPSESN	868	GGYDG	974	RSSQSL	1080	GISNRF	1186	LQGTH
20		YWMH				WDYFIY		AKSYG		S		QPYT
						Y		NTYLS
Antibody	657	GYTFTS	763	DPSESN	869	GGYDG	975	RSSQSL	1081	GISNRF	1187	LQGTH
21		YWMH				WDYLID		AKSYG		S		QPYT
						Y		NTYLS
Antibody	658	GYTFTS	764	DPSESN	870	GGYDG	976	RSSQSL	1082	GISNRF	1188	LQGTH
22		YWMH				WDYVI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	659	GYTFTS	765	DPSESN	871	GGYDG	977	RSSQSL	1083	GISNRF	1189	LQGTH
23		YWMH				WDYVI		AKSYG		S		QPYT
						YY		NTYLS
Antibody	660	GYTFTS	766	DPSESN	872	GGYDG	978	RSSQSL	1084	GISNRF	1190	LQGTH
24		YWMH				WDYWI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	661	GYTFTS	767	DPSESN	873	GGYDG	979	RSSQSL	1085	GISNRF	1191	LQGTH
25		YWMH				WDYYI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	662	GYTFTS	768	DPSESN	874	GGYDG	980	RSSQSL	1086	GISNRF	1192	LQGTH
26		YWMH				WDYYI		AKSYG		S		QPYT
						YY		NTYLS
Antibody	663	GYTFTS	769	DPSESN	875	GGYDG	981	RSSQSL	1087	GISNRF	1193	LQGTH
27		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	664	GYTFTS	770	DPSESN	876	GGYDG	982	RSSQSL	1088	GISNRF	1194	LQGTH
28		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	665	GYTFTS	771	DPSESN	877	GGYDG	983	RSSQSL	1089	GISNRF	1195	LQGTH
29		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	666	GYTFTS	772	DPSESN	878	GGYDG	984	RSSQSL	1090	GISNRF	1196	LQGTH
30		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	667	GYTFTS	773	DPSESN	879	GGYDG	985	RSSQSL	1091	GISNRF	1197	LQGTH
31		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	668	GYTFTS	774	DPSESN	880	GGYWG	986	RSSQSL	1092	GISNRF	1198	LQGTH
32		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	669	GYTFTS	775	DPSESN	881	GGYYG	987	RSSQSL	1093	GISNRF	1199	LQGTH
33		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	670	GYTFTS	776	DPSESN	882	GGYDG	988	RSSQSL	1094	GISNRF	1200	LQGTH
34		YWMH				WDYAIF		AKSYG		S		QPYT
						Y		NTYLS
Antibody	671	GYTFTS	777	DPSESN	883	GGYDG	989	RSSQSL	1095	GISNRF	1201	LQGTH
35		YWMH				WDYAI		AKSYG		S		QPYT
						MY		NTYLS
Antibody	672	GYTFTS	778	DPSESN	884	GGYDG	990	RSSQSL	1096	GISNRF	1202	LQGTH
36		YWMH				WDYAI		AKSYG		S		QPYT
						WY		NTYLS
Antibody	673	GYTFTS	779	DPSESN	885	GGYDG	991	RSSQSL	1097	GISNRF	1203	LQGTH
37		YWMH				WDYAI		AKSYG		S		QPYT
						YY		NTYLS
Antibody	674	GYTFTS	780	DPSESN	886	GFYDG	992	RSSQSL	1098	GISNRF	1204	LQGTH
38		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	675	GYTFTS	781	DPSESN	887	GFYDG	993	RSSQSL	1099	GISNRF	1205	LQGTH
39		YWMH				WDYLID		AKSYG		S		QPYT
						Y		NTYLS
Antibody	676	GYTFTS	782	DPSESN	888	GFYDG	994	RSSQSL	1100	GISNRF	1206	LQGTH
40		YWMH				WDYAI		AKSYG		S		QPYT
						YY		NTYLS
Antibody	677	GYTFTS	783	DPSESN	889	GMYDG	995	RSSQSL	1101	GISNRF	1207	LQGTH
41		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	678	GYTFTS	784	DPSESN	890	GRYDG	996	RSSQSL	1102	GISNRF	1208	LQGTH
42		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	679	GYTFTS	785	DPSESN	891	GVYDG	997	RSSQSL	1103	GISNRF	1209	LQGTH
43		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	680	GYTFTS	786	DPSESN	892	GGYDI	998	RSSQSL	1104	GISNRF	1210	LQGTH
44		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	681	GYTFTS	787	DPSESN	893	GGYDL	999	RSSQSL	1105	GISNRF	1211	LQGTH
45		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	682	GYTFTS	788	DPSESN	894	GGYDV	1000	RSSQSL	1106	GISNRF	1212	LQGTH
46		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	683	GYTFTS	789	DPSESN	895	FGYDG	1001	RSSQSL	1107	GISNRF	1213	LQGTH
47		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	684	GYTFTS	790	DPSESN	896	YGYDG	1002	RSSQSL	1108	GISNRF	1214	LQGTH
48		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	685	GYTFTS	791	DPSESN	897	GGYDG	1003	RSSQSL	1109	GISNRF	1215	LQGTH
49		YWMH				WDYAI		AASYG		S		QPYT
						DY		NTYLS
Antibody	686	GYTFTS	792	DPSESN	898	GGYDG	1004	RSSQSL	1110	GISNRF	1216	LQGTH
50		YWMH				WDYAI		ADSYG		S		QPYT
						DY		NTYLS
Antibody	687	GYTFTS	793	DPSESN	899	GGYDG	1005	RSSQSL	1111	GISNRF	1217	LQGTH
51		YWMH				WDYAI		AISYGN		S		QPYT
						DY		TYLS
Antibody	688	GYTFTS	794	DPSESN	900	GGYDG	1006	RSSQSL	1112	GISNRF	1218	LQGTH
52		YWMH				WDYAI		AIFYGN		S		QPYT
						DY		TYLS
Antibody	689	GYTFTS	795	DPSESN	901	GGYDG	1007	RSSQSL	1113	GISNRF	1219	LQGTH
53		YWMH				WDYAI		AIFYGIT		S		QPYT
						DY		YLS
Antibody	690	GYTFTS	796	DPSESN	902	GGYDG	1008	RSSQSL	1114	GISNRF	1220	LQGTH
54		YWMH				WDYAI		AIFYGL		S		QPYT
						DY		TYLS
Antibody	691	GYTFTS	797	DPSESN	903	GGYDG	1009	RSSQSL	1115	GISNRF	1221	LQGTH
55		YWMH				WDYAI		AILYGIT		S		QPYT
						DY		YLS
Antibody	692	GYTFTS	798	DPSESN	904	GGYDG	1010	RSSQSL	1116	GISNRF	1222	LQGTH
56		YWMH				WDYAI		AILYGL		S		QPYT
						DY		TYLS
Antibody	693	GYTFTS	799	DPSESN	905	GGYDG	1011	RSSQSL	1117	GISNRF	1223	LOGTH
57		YWMH				WDYAI		ALSYGN		S		QPYT
						DY		TYLS
Antibody	694	GYTFTS	800	DPSESN	906	GGYDG	1012	RSSQSL	1118	GISNRF	1224	LQGTH
58		YWMH				WDYAI		AMSYG		S		QPYT
						DY		NTYLS
Antibody	695	GYTFTS	801	DPSESN	907	GGYDG	1013	RSSQSL	1119	GISNRF	1225	LQGTH
59		YWMH				WDYAI		ANSYG		S		QPYT
						DY		NTYLS
Antibody	696	GYTFTS	802	DPSESN	908	GGYDG	1014	RSSQSL	1120	GISNRF	1226	LQGTH
60		YWMH				WDYAI		APSYGN		S		QPYT
						DY		TYLS
Antibody	697	GYTFTS	803	DPSESN	909	GGYDG	1015	RSSQSL	1121	GISNRF	1227	LQGTH
61		YWMH				WDYAI		AQSYG		S		QPYT
						DY		NTYLS
Antibody	698	GYTFTS	804	DPSESN	910	GGYDG	1016	RSSQSL	1122	GISNRF	1228	LQGTH
62		YWMH				WDYAI		ARSYG		S		QPYT
						DY		NTYLS
Antibody	699	GYTFTS	805	DPSESN	911	GGYDG	1017	RSSQSL	1123	GISNRF	1229	LQGTH
63		YWMH				WDYAI		ARFYGL		S		QPYT
						DY		TYLS
Antibody	700	GYTFTS	806	DPSESN	912	GGYDG	1018	RSSQSL	1124	GISNRF	1230	LQGTH
64		YWMH				WDYAI		ASSYGN		S		QPYT
						DY		TYLS
Antibody	701	GYTFTS	807	DPSESN	913	GGYDG	1019	RSSQSL	1125	GISNRF	1231	LQGTH
65		YWMH				WDYAI		ATSYGN		S		QPYT
						DY		TYLS
Antibody	702	GYTFTS	808	DPSESN	914	GGYDG	1020	RSSQSL	1126	GISNRF	1232	LQGTH
66		YWMH				WDYAI		ATYYGI		S		QPYT
						DY		TYLS
Antibody	703	GYTFTS	809	DPSESN	915	GGYDG	1021	RSSQSL	1127	GISNRF	1233	LQGTH
67		YWMH				WDYAI		ATYYG		S		QPYT
						DY		LTYLS
Antibody	704	GYTFTS	810	DPSESN	916	GGYDG	1022	RSSQSL	1128	GISNRF	1234	LQGTH
68		YWMH				WDYAI		AVSYG		S		QPYT
						DY		NTYLS
Antibody	705	GYTFTS	811	DPSESN	917	GGYDG	1023	RSSQSL	1129	GISNRF	1235	LOGTH
69		YWMH				WDYAI		AYSYG		S		QPYT
						DY		NTYLS
Antibody	706	GYTFTS	812	DPSESN	918	GGYDG	1024	RSSQSL	1130	GISNRF	1236	LQGTH
70		YWMH				WDYAI		AYFYGI		S		QPYT
						DY		TYLS
Antibody	707	GYTFTS	813	DPSESN	919	GGYDG	1025	RSSQSL	1131	GISNRF	1237	LQGTH
71		YWMH				WDYAI		AYLYGI		S		QPYT
						DY		TYLS
Antibody	708	GYTFTS	814	DPSESN	920	GGYDG	1026	RSSQSL	1132	GISNRF	1238	LQGTH
72		YWMH				WDYAI		AKSYGI		S		QPYT
						DY		TYLS
Antibody	709	GYTFTS	815	DPSESN	921	GGYDG	1027	RSSQSL	1133	GISNRF	1239	LOGTH
73		YWMH				WDYAI		AKSYGL		S		QPYT
						DY		TYLS
Antibody	710	GYTFTS	816	DPSESN	922	GGYDG	1028	RSSQSL	1134	GISNRF	1240	LQGTH
74		YWMH				WDYAI		AKFYG		S		QPYT
						DY		NTYLS
Antibody	711	GYTFTS	817	DPSESN	923	GGYDG	1029	RSSQSL	1135	GISNRF	1241	LQGTH
75		YWMH				WDYAI		AKIYGN		S		QPYT
						DY		TYLS
Antibody	712	GYTFTS	818	DPSESN	924	GGYDG	1030	RSSQSL	1136	GISNRF	1242	LQGTH
76		YWMH				WDYAI		AKLYG		S		QPYT
						DY		NTYLS
Antibody	713	GYTFTS	819	DPSESN	925	GGYDG	1031	RSSQSL	1137	GISNRF	1243	LQGTH
77		YWMH				WDYAI		AKMYG		S		QPYT
						DY		NTYLS
Antibody	714	GYTFTS	820	DPSESN	926	GGYDG	1032	RSSQSL	1138	GISNRF	1244	LQGTH
78		YWMH				WDYAI		AKQYG		S		QPYT
						DY		NTYLS
Antibody	715	GYTFTS	821	DPSESN	927	GGYDG	1033	RSSQSL	1139	GISNRF	1245	LQGTH
79		YWMH				WDYAI		AKYYG		S		QPYT
						DY		NTYLS
Antibody	716	GYTFTS	822	DPSESN	928	GGYDG	1034	RSSQSL	1140	GISNRF	1246	LQGTH
80		YWMH				WDYAI		AKSHG		S		QPYT
						DY		NTYLS
Antibody	717	GYTFTS	823	DPSESN	929	GGYDG	1035	RSSQSL	1141	FISNRFS	1247	LQGTH
81		YWMH				WDYAI		AKSYG				QPYT
						DY		NTYLS
Antibody	718	GYTFTS	824	DPSESN	930	GGYDG	1036	RSSQSL	1142	PISNRFS	1248	LOGTH
82		YWMH				WDYAI		AKSYG				QPYT
						DY		NTYLS
Antibody	719	GYTFTS	825	DPSESN	931	GGYDG	1037	RSSQSL	1143	YISNRF	1249	LQGTH
83		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	720	GYTFTS	826	DPSESN	932	GGYDG	1038	RSSQSL	1144	GISNRF	1250	LQFTHQ
84		YWMH				WDYAI		AKSYG		S		PYT
						DY		NTYLS
Antibody	721	GYTFTS	827	DPSESN	933	GGYDG	1039	RSSQSL	1145	GISNRF	1251	LQFTIQ
85		YWMH				WDYAI		AKSYG		S		FYT
						DY		NTYLS
Antibody	722	GYTFTS	828	DPSESN	934	GGYDG	1040	RSSQSL	1146	GISNRF	1252	LQFTIQ
86		YWMH				WDYAI		AKSYG		S		VYT
						DY		NTYLS
Antibody	723	GYTFTS	829	DPSESN	935	GGYDG	1041	RSSQSL	1147	GISNRF	1253	LQFTIQ
87		YWMH				WDYAI		AKSYG		S		PYI
						DY		NTYLS
Antibody	724	GYTFTS	830	DPSESN	936	GGYDG	1042	RSSQSL	1148	GISNRF	1254	LQFTHQ
88		YWMH				WDYAI		AKSYG		S		FYT
						DY		NTYLS
Antibody	725	GYTFTS	831	DPSESN	937	GGYDG	1043	RSSQSL	1149	GISNRF	1255	LQFTHQ
89		YWMH				WDYAI		AKSYG		S		IYI
						DY		NTYLS
Antibody	726	GYTFTS	832	DPSESN	938	GGYDG	1044	RSSQSL	1150	GISNRF	1256	LQFTHQ
90		YWMH				WDYAI		AKSYG		S		PYI
						DY		NTYLS
Antibody	727	GYTFTS	833	DPSESN	939	GGYDG	1045	RSSQSL	1151	GISNRF	1257	LQRTHQ
91		YWMH				WDYAI		AKSYG		S		PYT
						DY		NTYLS
Antibody	728	GYTFTS	834	DPSESN	940	GGYDG	1046	RSSQSL	1152	GISNRF	1258	LQRTIQ
92		YWMH				WDYAI		AKSYG		S		VYI
						DY		NTYLS
Antibody	729	GYTFTS	835	DPSESN	941	GGYDG	1047	RSSQSL	1153	GISNRF	1259	LQRTIQ
93		YWMH				WDYAI		AKSYG		S		YYT
						DY		NTYLS
Antibody	730	GYTFTS	836	DPSESN	942	GGYDG	1048	RSSQSL	1154	GISNRF	1260	LQVTH
94		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	731	GYTFTS	837	DPSESN	943	GGYDG	1049	RSSQSL	1155	GISNRF	1261	LQWTH
95		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	732	GYTFTS	838	DPSESN	944	GGYDG	1050	RSSQSL	1156	GISNRF	1262	LQYTH
96		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	733	GYTFTS	839	DPSESN	945	GGYDG	1051	RSSQSL	1157	GISNRF	1263	LQYTIQ
97		YWMH				WDYAI		AKSYG		S		FYI
						DY		NTYLS
Antibody	734	GYTFTS	840	DPSESN	946	GGYDG	1052	RSSQSL	1158	GISNRF	1264	LQYTH
98		YWMH				WDYAI		AKSYG		S		QFYI
						DY		NTYLS
Antibody	735	GYTFTS	841	DPSESN	947	GGYDG	1053	RSSQSL	1159	GISNRF	1265	LQGTIQ
99		YWMH				WDYAI		AKSYG		S		PYT
						DY		NTYLS
Antibody	736	GYTFTS	842	DPSESN	948	GGYDG	1054	RSSQSL	1160	GISNRF	1266	LQGTW
100		YWMH				WDYAI		AKSYG		S		QPYT
						DY		NTYLS
Antibody	737	GYTFTS	843	DPSESN	949	GGYDG	1055	RSSQSL	1161	GISNRF	1267	LQGTH
101		YWMH				WDYAI		AKSYG		S		QFYT
						DY		NTYLS
Antibody	738	GYTFTS	844	DPSESN	950	GGYDG	1056	RSSQSL	1162	GISNRF	1268	LQGTH
102		YWMH				WDYAI		AKSYG		S		QIYT
						DY		NTYLS
Antibody	739	GYTFTS	845	DPSESN	951	GGYDG	1057	RSSQSL	1163	GISNRF	1269	LQGTH
103		YWMH				WDYAI		AKSYG		S		QVYT
						DY		NTYLS
Antibody	740	GYTFTS	846	DPSESN	952	GGYDG	1058	RSSQSL	1164	GISNRF	1270	LQGTH
104		YWMH				WDYAI		AKSYG		S		QYYT
						DY		NTYLS
Antibody	741	GYTFTS	847	DPSESN	953	GGYDG	1059	RSSQSL	1165	GISNRF	1271	LQGTH
105		YWMH				WDYAI		AKSYG		S		QPYI
						DY		NTYLS
Antibody	742	GYTFTS	848	DPSESN	954	GGYDG	1060	RSSQSL	1166	GISNRF	1272	LQGTH
106		YWMH				WDYAI		AKSYG		S		QPYR
						DY		NTYLS
IMGT Numbering
Antibody 1	1273	GGTFTS	1379	IDPSESN	1485	ARGGY	1591	QSLAKS		GIS	1803	LQGTH
		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody 2	1274	GYTFTS	1380	IDPSESN	1486	ARGGY	1592	QSLAKS		GIS	1804	LQGTH
						DGWDY
		YW		T		AIDY		YGNTY				QPYT
Antibody 3	1275	GYTFTI	1381	IDPSESN	1487	ARGGY	1593	QSLAKS		GIS	1805	LQGTH
		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody 4	1276	GYTFTV	1382	IDPSESN	1488	ARGGY	1594	QSLAKS		GIS	1806	LQGTH
		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody 5	1277	GYTFTS	1383	IDPSESN	1489	ARGGY	1595	QSLAKS		GIS	1807	LQGTH
		MW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody 6	1278	GYTFTS	1384	IDPSESN	1490	ARGGY	1596	QSLAKS		GIS	1808	LQGTH
		QW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody 7	1279	GYTFTS	1385	IIPSESN	1491	ARGGY	1597	QSLAKS		GIS	1809	LQGTH
		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody 8	1280	GYTFTS	1386	IIPLESN	1492	ARGGY	1598	QSLAKS		GIS	1810	LQGTH
		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody 9	1281	GYTFTS	1387	IIPRESN	1493	ARGGY	1599	QSLAKS		GIS	1811	LQGTH
		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1282	GYTFTS	1388	IIPVESN	1494	ARGGY	1600	QSLAKS		GIS	1812	LQGTH
10		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1283	GYTFTS	1389	IRPSESN	1495	ARGGY	1601	QSLAKS		GIS	1813	LQGTH
11		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1284	GYTFTS	1390	IRPLESN	1496	ARGGY	1602	QSLAKS		GIS	1814	LQGTH
12		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1285	GYTFTS	1391	IRPRES	1497	ARGGY	1603	QSLAKS		GIS	1815	LQGTH
13		YW		NT		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1286	GYTFTS	1392	IRPVES	1498	ARGGY	1604	QSLAKS		GIS	1816	LQGTH
14		YW		NT		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1287	GYTFTS	1393	IDPLES	1499	ARGGY	1605	QSLAKS		GIS	1817	LQGTH
15		YW		NT		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1288	GYTFTS	1394	IDPMES	1500	ARGGY	1606	QSLAKS		GIS	1818	LQGTH
16		YW		NT		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1289	GYTFTS	1395	IDPRES	1501	ARGGY	1607	QSLAKS		GIS	1819	LQGTH
17		YW		NT		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1290	GYTFTS	1396	IDPVES	1502	ARGGY	1608	QSLAKS		GIS	1820	LQGTH
18		YW		NT		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1291	GYTFTS	1397	IDPSESN	1503	ARGGY	1609	QSLAKS		GIS	1821	LQGTH
19		YW		T		DGWDY		YGNTY				QPYT
						FIDY
Antibody	1292	GYTFTS	1398	IDPSESN	1504	ARGGY	1610	QSLAKS		GIS	1822	LQGTH
20		YW		T		DGWDY		YGNTY				QPYT
						FIYY
Antibody	1293	GYTFTS	1399	IDPSESN	1505	ARGGY	1611	QSLAKS		GIS	1823	LQGTH
21		YW		T		DGWDY		YGNTY				QPYT
						LIDY
Antibody	1294	GYTFTS	1400	IDPSESN	1506	ARGGY	1612	QSLAKS		GIS	1824	LQGTH
22		YW		T		DGWDY		YGNTY				QPYT
						VIDY
Antibody	1295	GYTFTS	1401	IDPSESN	1507	ARGGY	1613	QSLAKS		GIS	1825	LOGTH
23		YW		T		DGWDY		YGNTY				QPYT
						VIYY
Antibody	1296	GYTFTS	1402	IDPSESN	1508	ARGGY	1614	QSLAKS		GIS	1826	LQGTH
24		YW		T		DGWDY		YGNTY				QPYT
						WIDY
Antibody	1297	GYTFTS	1403	IDPSESN	1509	ARGGY	1615	QSLAKS		GIS	1827	LQGTH
25		YW		T		DGWDY		YGNTY				QPYT
						YIDY
Antibody	1298	GYTFTS	1404	IDPSESN	1510	ARGGY	1616	QSLAKS		GIS	1828	LQGTH
26		YW		T		DGWDY		YGNTY				QPYT
						YIYY
Antibody	1299	GYTFTS	1405	IDPSESN	1511	IRGGYD	1617	QSLAKS		GIS	1829	LQGTH
27		YW		T		GWDYA		YGNTY				QPYT
						IDY
Antibody	1300	GYTFTS	1406	IDPSESN	1512	LRGGY	1618	QSLAKS		GIS	1830	LQGTH
28		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1301	GYTFTS	1407	IDPSESN	1513	MRGGY	1619	QSLAKS		GIS	1831	LOGTH
29		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1302	GYTFTS	1408	IDPSESN	1514	RRGGY	1620	QSLAKS		GIS	1832	LQGTH
30		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1303	GYTFTS	1409	IDPSESN	1515	VRGGY	1621	QSLAKS		GIS	1833	LQGTH
31		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1304	GYTFTS	1410	IDPSESN	1516	ARGGY	1622	QSLAKS		GIS	1834	LQGTH
32		YW		T		WGWDY		YGNTY				QPYT
						AIDY
Antibody	1305	GYTFTS	1411	IDPSESN	1517	ARGGY	1623	QSLAKS		GIS	1835	LQGTH
33		YW		T		YGWDY		YGNTY				QPYT
						AIDY
Antibody	1306	GYTFTS	1412	IDPSESN	1518	ARGGY	1624	QSLAKS		GIS	1836	LQGTH
34		YW		T		DGWDY		YGNTY				QPYT
						AIFY
Antibody	1307	GYTFTS	1413	IDPSESN	1519	ARGGY	1625	QSLAKS		GIS	1837	LQGTH
35		YW		T		DGWDY		YGNTY				QPYT
						AIMY
Antibody	1308	GYTFTS	1414	IDPSESN	1520	ARGGY	1626	QSLAKS		GIS	1838	LOGTH
36		YW		T		DGWDY		YGNTY				QPYT
						AIWY
Antibody	1309	GYTFTS	1415	IDPSESN	1521	ARGGY	1627	QSLAKS		GIS	1839	LQGTH
37		YW		T		DGWDY		YGNTY				QPYT
						AIYY
Antibody	1310	GYTFTS	1416	IDPSESN	1522	ARGFY	1628	QSLAKS		GIS	1840	LQGTH
38		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1311	GYTFTS	1417	IDPSESN	1523	ARGFY	1629	QSLAKS		GIS	1841	LQGTH
39		YW		T		DGWDY		YGNTY				QPYT
						LIDY
Antibody	1312	GYTFTS	1418	IDPSESN	1524	ARGFY	1630	QSLAKS		GIS	1842	LQGTH
40		YW		T		DGWDY		YGNTY				QPYT
						AIYY
Antibody	1313	GYTFTS	1419	IDPSESN	1525	ARGMY	1631	QSLAKS		GIS	1843	LQGTH
41		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1314	GYTFTS	1420	IDPSESN	1526	ARGRY	1632	QSLAKS		GIS	1844	LQGTH
42		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1315	GYTFTS	1421	IDPSESN	1527	ARGVY	1633	QSLAKS		GIS	1845	LQGTH
43		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1316	GYTFTS	1422	IDPSESN	1528	ARGGY	1634	QSLAKS		GIS	1846	LQGTH
44		YW		T		DIWDY		YGNTY				QPYT
						AIDY
Antibody	1317	GYTFTS	1423	IDPSESN	1529	ARGGY	1635	QSLAKS		GIS	1847	LQGTH
45		YW		T		DLWDY		YGNTY				QPYT
						AIDY
Antibody	1318	GYTFTS	1424	IDPSESN	1530	ARGGY	1636	QSLAKS		GIS	1848	LQGTH
46		YW		T		DVWDY		YGNTY				QPYT
						AIDY
Antibody	1319	GYTFTS	1425	IDPSESN	1531	ARFGY	1637	QSLAKS		GIS	1849	LQGTH
47		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1320	GYTFTS	1426	IDPSESN	1532	ARYGY	1638	QSLAKS		GIS	1850	LQGTH
48		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1321	GYTFTS	1427	IDPSESN	1533	ARGGY	1639	QSLAAS		GIS	1851	LQGTH
49		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1322	GYTFTS	1428	IDPSESN	1534	ARGGY	1640	QSLADS		GIS	1852	LQGTH
50		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1323	GYTFTS	1429	IDPSESN	1535	ARGGY	1641	QSLAIS		GIS	1853	LQGTH
51		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1324	GYTFTS	1430	IDPSESN	1536	ARGGY	1642	QSLAIF		GIS	1854	LQGTH
52		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1325	GYTFTS	1431	IDPSESN	1537	ARGGY	1643	QSLAIF		GIS	1855	LQGTH
53		YW		T		DGWDY		YGITY				QPYT
						AIDY
Antibody	1326	GYTFTS	1432	IDPSESN	1538	ARGGY	1644	QSLAIF		GIS	1856	LQGTH
54		YW		T		DGWDY		YGLTY				QPYT
						AIDY
Antibody	1327	GYTFTS	1433	IDPSESN	1539	ARGGY	1645	QSLAIL		GIS	1857	LQGTH
55		YW		T		DGWDY		YGITY				QPYT
						AIDY
Antibody	1328	GYTFTS	1434	IDPSESN	1540	ARGGY	1646	QSLAIL		GIS	1858	LQGTH
56		YW		T		DGWDY		YGLTY				QPYT
						AIDY
Antibody	1329	GYTFTS	1435	IDPSESN	1541	ARGGY	1647	QSLALS		GIS	1859	LQGTH
57		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1330	GYTFTS	1436	IDPSESN	1542	ARGGY	1648	QSLAMS		GIS	1860	LQGTH
58		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1331	GYTFTS	1437	IDPSESN	1543	ARGGY	1649	QSLANS		GIS	1861	LQGTH
59		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1332	GYTFTS	1438	IDPSESN	1544	ARGGY	1650	QSLAPS		GIS	1862	LQGTH
60		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1333	GYTFTS	1439	IDPSESN	1545	ARGGY	1651	QSLAQS		GIS	1863	LQGTH
61		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1334	GYTFTS	1440	IDPSESN	1546	ARGGY	1652	QSLARS		GIS	1864	LQGTH
62		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1335	GYTFTS	1441	IDPSESN	1547	ARGGY	1653	QSLARF		GIS	1865	LQGTH
63		YW		T		DGWDY		YGLTY				QPYT
						AIDY
Antibody	1336	GYTFTS	1442	IDPSESN	1548	ARGGY	1654	QSLASS		GIS	1866	LQGTH
64		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1337	GYTFTS	1443	IDPSESN	1549	ARGGY	1655	QSLATS		GIS	1867	LQGTH
65		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1338	GYTFTS	1444	IDPSESN	1550	ARGGY	1656	QSLATY		GIS	1868	LQGTH
66		YW		T		DGWDY		YGITY				QPYT
						AIDY
Antibody	1339	GYTFTS	1445	IDPSESN	1551	ARGGY	1657	QSLATY		GIS	1869	LQGTH
67		YW		T		DGWDY		YGLTY				QPYT
						AIDY
Antibody	1340	GYTFTS	1446	IDPSESN	1552	ARGGY	1658	QSLAVS		GIS	1870	LQGTH
68		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1341	GYTFTS	1447	IDPSESN	1553	ARGGY	1659	QSLAYS		GIS	1871	LQGTH
69		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1342	GYTFTS	1448	IDPSESN	1554	ARGGY	1660	QSLAYF		GIS	1872	LQGTH
70		YW		T		DGWDY		YGITY				QPYT
						AIDY
Antibody	1343	GYTFTS	1449	IDPSESN	1555	ARGGY	1661	QSLAYL		GIS	1873	LQGTH
71		YW		T		DGWDY		YGITY				QPYT
						AIDY
Antibody	1344	GYTFTS	1450	IDPSESN	1556	ARGGY	1662	QSLAKS		GIS	1874	LQGTH
72		YW		T		DGWDY		YGITY				QPYT
						AIDY
Antibody	1345	GYTFTS	1451	IDPSESN	1557	ARGGY	1663	QSLAKS		GIS	1875	LQGTH
73		YW		T		DGWDY		YGLTY				QPYT
						AIDY
Antibody	1346	GYTFTS	1452	IDPSESN	1558	ARGGY	1664	QSLAKF		GIS	1876	LQGTH
74		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1347	GYTFTS	1453	IDPSESN	1559	ARGGY	1665	QSLAKI		GIS	1877	LQGTH
75		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1348	GYTFTS	1454	IDPSESN	1560	ARGGY	1666	QSLAKL		GIS	1878	LQGTH
76		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1349	GYTFTS	1455	IDPSESN	1561	ARGGY	1667	QSLAK		GIS	1879	LQGTH
77		YW		T		DGWDY		MYGNT				QPYT
						AIDY		Y
Antibody	1350	GYTFTS	1456	IDPSESN	1562	ARGGY	1668	QSLAKQ		GIS	1880	LQGTH
78		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1351	GYTFTS	1457	IDPSESN	1563	ARGGY	1669	QSLAKY		GIS	1881	LQGTH
79		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1352	GYTFTS	1458	IDPSESN	1564	ARGGY	1670	QSLAKS		GIS	1882	LQGTH
80		YW		T		DGWDY		HGNTY				QPYT
						AIDY
Antibody	1353	GYTFTS	1459	IDPSESN	1565	ARGGY	1671	QSLAKS		FIS	1883	LQGTH
81		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1354	GYTFTS	1460	IDPSESN	1566	ARGGY	1672	QSLAKS		PIS	1884	LQGTH
82		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1355	GYTFTS	1461	IDPSESN	1567	ARGGY	1673	QSLAKS		YIS	1885	LQGTH
83		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1356	GYTFTS	1462	IDPSESN	1568	ARGGY	1674	QSLAKS		GIS	1886	LQFTHQ
84		YW		T		DGWDY		YGNTY				PYT
						AIDY
Antibody	1357	GYTFTS	1463	IDPSESN	1569	ARGGY	1675	QSLAKS		GIS	1887	LQFTIQ
85		YW		T		DGWDY		YGNTY				FYT
						AIDY
Antibody	1358	GYTFTS	1464	IDPSESN	1570	ARGGY	1676	QSLAKS		GIS	1888	LQFTIQ
86		YW		T		DGWDY		YGNTY				VYT
						AIDY
Antibody	1359	GYTFTS	1465	IDPSESN	1571	ARGGY	1677	QSLAKS		GIS	1889	LQFTIQ
87		YW		T		DGWDY		YGNTY				PYI
						AIDY
Antibody	1360	GYTFTS	1466	IDPSESN	1572	ARGGY	1678	QSLAKS		GIS	1890	LQFTHQ
88		YW		T		DGWDY		YGNTY				FYT
						AIDY
Antibody	1361	GYTFTS	1467	IDPSESN	1573	ARGGY	1679	QSLAKS		GIS	1891	LQFTHQ
89		YW		T		DGWDY		YGNTY				IYI
						AIDY
Antibody	1362	GYTFTS	1468	IDPSESN	1574	ARGGY	1680	QSLAKS		GIS	1892	LQFTHQ
90		YW		T		DGWDY		YGNTY				PYI
						AIDY
Antibody	1363	GYTFTS	1469	IDPSESN	1575	ARGGY	1681	QSLAKS		GIS	1893	LQRTHQ
91		YW		T		DGWDY		YGNTY				PYT
						AIDY
Antibody	1364	GYTFTS	1470	IDPSESN	1576	ARGGY	1682	QSLAKS		GIS	1894	LQRTIQ
92		YW		T		DGWDY		YGNTY				VYI
						AIDY
Antibody	1365	GYTFTS	1471	IDPSESN	1577	ARGGY	1683	QSLAKS		GIS	1895	LQRTIQ
93		YW		T		DGWDY		YGNTY				YYT
						AIDY
Antibody	1366	GYTFTS	1472	IDPSESN	1578	ARGGY	1684	QSLAKS		GIS	1896	LQVTH
94		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1367	GYTFTS	1473	IDPSESN	1579	ARGGY	1685	QSLAKS		GIS	1897	LQWTH
95		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1368	GYTFTS	1474	IDPSESN	1580	ARGGY	1686	QSLAKS		GIS	1898	LQYTH
96		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1369	GYTFTS	1475	IDPSESN	1581	ARGGY	1687	QSLAKS		GIS	1899	LQYTIQ
97		YW		T		DGWDY		YGNTY				FYI
						AIDY
Antibody	1370	GYTFTS	1476	IDPSESN	1582	ARGGY	1688	QSLAKS		GIS	1900	LQYTH
98		YW		T		DGWDY		YGNTY				QFYI
						AIDY
Antibody	1371	GYTFTS	1477	IDPSESN	1583	ARGGY	1689	QSLAKS		GIS	1901	LQGTIQ
99		YW		T		DGWDY		YGNTY				PYT
						AIDY
Antibody	1372	GYTFTS	1478	IDPSESN	1584	ARGGY	1690	QSLAKS		GIS	1902	LQGTW
100		YW		T		DGWDY		YGNTY				QPYT
						AIDY
Antibody	1373	GYTFTS	1479	IDPSESN	1585	ARGGY	1691	QSLAKS		GIS	1903	LQGTH
101		YW		T		DGWDY		YGNTY				QFYT
						AIDY
Antibody	1374	GYTFTS	1480	IDPSESN	1586	ARGGY	1692	QSLAKS		GIS	1904	LQGTH
102		YW		T		DGWDY		YGNTY				QIYT
						AIDY
Antibody	1375	GYTFTS	1481	IDPSESN	1587	ARGGY	1693	QSLAKS		GIS	1905	LQGTH
103		YW		T		DGWDY		YGNTY				QVYT
						AIDY
Antibody	1376	GYTFTS	1482	IDPSESN	1588	ARGGY	1694	QSLAKS		GIS	1906	LQGTH
104		YW		T		DGWDY		YGNTY				QYYT
						AIDY
Antibody	1377	GYTFTS	1483	IDPSESN	1589	ARGGY	1695	QSLAKS		GIS	1907	LQGTH
105		YW		T		DGWDY		YGNTY				QPYI
						AIDY
Antibody	1378	GYTFTS	1484	IDPSESN	1590	ARGGY	1696	QSLAKS		GIS	1908	LQGTH
106		YW		T		DGWDY		YGNTY				QPYR
						AIDY